Clarification of Optimal Anticoagulation Through Genetics

PHASE3CompletedINTERVENTIONAL
Enrollment

1,015

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

April 30, 2013

Study Completion Date

November 30, 2013

Conditions
StrokeVenous ThrombosisAtrial FibrillationAtrial Flutter
Interventions
BEHAVIORAL

Genotype-guided dosing algorithm for warfarin

Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical and genetic information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical and genetic information.

BEHAVIORAL

Clinical-guided dosing algorithm for warfarin

Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical information.

Trial Locations (18)

10029

Mount Sinai School of Medicine, New York

10467

Montefiore Medical Center, The Bronx

19104

Hospital of the University of Pennsylvania, Philadelphia

21201

University of Maryland School of Medicine, Baltimore

27710

Duke University, Durham

30912

Georgia Health Sciences University, Augusta

35249

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University, Nashville

48202

Henry Ford Hospital, Detroit

54449

Marshfield Clinical Research Foundation, Marshfield

55905

Mayo Clinic College of Medicine, Rochester

63110

Washington University School of Medicine, St Louis

70112

Tulane University Health Science Center, New Orleans

77555

University of Texas Medical Branch, Galveston

84132

University of Utah Health Care, Salt Lake City

04143-0131

University of California San Francisco, San Francisco

32610-0486

University of Florida, Gainesville

84157-7000

Intermountain Medical Center, Murray

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH